Published in J Am Coll Cardiol on January 23, 2007
Echocardiography, natriuretic peptides, and risk for incident heart failure in older adults: the Cardiovascular Health Study. JACC Cardiovasc Imaging (2012) 2.15
Amino-terminal pro-B-type natriuretic peptide and high-sensitivity C-reactive protein as predictors of sudden cardiac death among women. Circulation (2009) 1.74
Prediction of ESRD and death among people with CKD: the Chronic Renal Impairment in Birmingham (CRIB) prospective cohort study. Am J Kidney Dis (2010) 1.65
Change in N-terminal-pro-B-type-natriuretic-peptide and the risk of sudden death, stroke, myocardial infarction, and all-cause mortality in diabetic dialysis patients. Eur Heart J (2008) 1.05
Effects of simvastatin 40 mg daily on muscle and liver adverse effects in a 5-year randomized placebo-controlled trial in 20,536 high-risk people. BMC Clin Pharmacol (2009) 1.01
Statin treatment for patients with heart failure. Nat Rev Cardiol (2010) 0.94
Biomarkers and cardiovascular risk assessment for primary prevention: an update. Clin Chem (2011) 0.89
Effect of obstructive sleep apnea hypopnea syndrome on lipid profile: a meta-regression analysis. J Clin Sleep Med (2014) 0.88
Statins in heart failure: do we need another trial? Vasc Health Risk Manag (2013) 0.88
Effect of CPAP treatment for obstructive sleep apnea hypopnea syndrome on lipid profile: a meta-regression analysis. J Clin Sleep Med (2014) 0.85
Biomarkers of atherosclerosis: clinical applications. Curr Cardiol Rep (2008) 0.83
The case for statin therapy in chronic heart failure. Clin Res Cardiol (2007) 0.81
Prediction of cardiovascular events in statin-treated stable coronary patients of the treating to new targets randomized controlled trial by lipid and non-lipid biomarkers. PLoS One (2014) 0.80
Lipophilic versus hydrophilic statin therapy for heart failure: a protocol for an adjusted indirect comparison meta-analysis. Syst Rev (2013) 0.80
N-terminal pro-brain-type natriuretic peptide (NT-pro-BNP) and mortality risk in early inflammatory polyarthritis: results from the Norfolk Arthritis Registry (NOAR). Ann Rheum Dis (2013) 0.78
Natriuretic Peptide testing in primary care. Curr Cardiol Rev (2008) 0.77
Statin therapy decreases N-terminal pro-B-type natriuretic peptide in HIV: randomized placebo-controlled trial. AIDS (2015) 0.76
Should a statin be prescribed to every patient with heart failure? Heart Fail Rev (2007) 0.76
All cholesterol-lowering interventions are expected to reduce stroke: Confirmatory data from IMPROVE-IT. Data Brief (2016) 0.75
Treatment strategies for the prevention of heart failure. Curr Heart Fail Rep (2013) 0.75
Lipids, statins, and clinical outcomes in heart failure: rethinking the data. Heart Fail Rev (2014) 0.75
Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet (2002) 40.37
Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet (2009) 26.09
Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet (2008) 25.83
Common variants at 30 loci contribute to polygenic dyslipidemia. Nat Genet (2008) 20.66
Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet (2007) 15.27
MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet (2003) 13.69
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet (2009) 13.64
C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet (2009) 11.81
Major lipids, apolipoproteins, and risk of vascular disease. JAMA (2009) 10.58
Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med (2014) 9.25
Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. Lancet (2011) 9.07
Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med (2009) 8.73
Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet (2012) 7.59
Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: Meta-analysis of 8 randomized trials involving 37 485 individuals. Arch Intern Med (2010) 6.48
Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate. JAMA (2012) 6.26
Unravelling the fetal origins hypothesis: is there really an inverse association between birthweight and subsequent blood pressure? Lancet (2002) 5.91
Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA (2009) 5.63
Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA (2005) 5.60
Genetic Loci associated with C-reactive protein levels and risk of coronary heart disease. JAMA (2009) 5.32
Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet (2004) 5.19
Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet (2010) 4.46
Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. Lancet (2010) 4.23
Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20,536 individuals. Lancet (2005) 4.20
Susceptibility to coronary artery disease and diabetes is encoded by distinct, tightly linked SNPs in the ANRIL locus on chromosome 9p. Hum Mol Genet (2007) 4.09
Association of apolipoprotein E genotypes with lipid levels and coronary risk. JAMA (2007) 4.03
New models for large prospective studies: is there a better way? Am J Epidemiol (2012) 3.85
Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet (2015) 3.79
Passive smoking and risk of coronary heart disease and stroke: prospective study with cotinine measurement. BMJ (2004) 3.66
Analyses of cancer data from three ezetimibe trials. N Engl J Med (2008) 3.44
Lipids and lipoproteins and risk of different vascular events in the MRC/BHF Heart Protection Study. Circulation (2012) 2.90
China Kadoorie Biobank of 0.5 million people: survey methods, baseline characteristics and long-term follow-up. Int J Epidemiol (2011) 2.82
Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66,155 cases and 91,307 controls. Lancet (2006) 2.72
Cohort profile: the Kadoorie Study of Chronic Disease in China (KSCDC). Int J Epidemiol (2005) 2.70
Fibrinogen and coronary heart disease: test of causality by 'Mendelian randomization'. Int J Epidemiol (2006) 2.68
Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people. BMJ (2006) 2.67
The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closure. Eur Heart J (2008) 2.65
Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA). Diabetes Care (2005) 2.59
Cholesterol fractions and apolipoproteins as risk factors for heart disease mortality in older men. Arch Intern Med (2007) 2.55
Four paraoxonase gene polymorphisms in 11212 cases of coronary heart disease and 12786 controls: meta-analysis of 43 studies. Lancet (2004) 2.55
Ensuring trial validity by data quality assurance and diversification of monitoring methods. Clin Trials (2008) 2.50
Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study. Am J Respir Crit Care Med (2005) 2.49
A statin-dependent QTL for GATM expression is associated with statin-induced myopathy. Nature (2013) 2.46
Randomized clinical trials--removing unnecessary obstacles. N Engl J Med (2013) 2.43
Large-scale evidence that the cardiotoxicity of smoking is not significantly modified by the apolipoprotein E epsilon2/epsilon3/epsilon4 genotype. Lancet (2003) 2.40
Effects of folic acid supplementation on overall and site-specific cancer incidence during the randomised trials: meta-analyses of data on 50,000 individuals. Lancet (2013) 2.37
First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. Am J Kidney Dis (2005) 2.36
Genetically determined height and coronary artery disease. N Engl J Med (2015) 2.24
Genome-wide association identifies nine common variants associated with fasting proinsulin levels and provides new insights into the pathophysiology of type 2 diabetes. Diabetes (2011) 2.21
Sensible approaches for reducing clinical trial costs. Clin Trials (2008) 2.20
Galectin-3 and cardiac function in survivors of acute myocardial infarction. Circ Heart Fail (2013) 2.17
Left atrial radiofrequency ablation during mitral valve surgery for continuous atrial fibrillation: a randomized controlled trial. JAMA (2005) 2.01
Plasma matrix metalloproteinase-9 and left ventricular remodelling after acute myocardial infarction in man: a prospective cohort study. Eur Heart J (2007) 1.99
Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. PLoS One (2012) 1.93
Is birth weight a risk factor for ischemic heart disease in later life? Am J Clin Nutr (2007) 1.93
Growth differentiation factor-15 as a prognostic marker in patients with acute myocardial infarction. Eur Heart J (2009) 1.90
Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic review. Lancet (2002) 1.79
Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the Heart Protection Study. Eur Heart J (2012) 1.75